

# Axel Finckh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2974518/publications.pdf>

Version: 2024-02-01

111  
papers

9,864  
citations

117625

34  
h-index

38395

95  
g-index

113  
all docs

113  
docs citations

113  
times ranked

9552  
citing authors

#	ARTICLE	IF	CITATIONS
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.9	3,366
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.9	1,860
3	Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. <i>Arthritis and Rheumatism</i> , 2006, 55, 864-872.	6.7	410
4	EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 638-641.	0.9	354
5	<i>Prevotella copri</i> in individuals at risk for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 590-593.	0.9	279
6	Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. <i>Arthritis Research and Therapy</i> , 2009, 11, S1.	3.5	227
7	B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. <i>Arthritis and Rheumatism</i> , 2007, 56, 1417-1423.	6.7	192
8	Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 965-973.	0.9	179
9	A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 40, 2-14.e1.	3.4	161
10	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48.	0.9	153
11	Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 386-391.	0.9	150
12	Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional study. <i>Lancet Rheumatology</i> , The, 2020, 2, e418-e427.	3.9	91
13	Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e1037-e1045.	5.8	90
14	Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban women. <i>Arthritis and Rheumatism</i> , 2006, 54, 3648-3654.	6.7	89
15	EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1596-1602.	0.9	87
16	Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents. <i>Annals of Internal Medicine</i> , 2009, 151, 612.	3.9	86
17	Short-Term Efficacy of Intravenous Pulse Glucocorticoids in Acute Discogenic Sciatica. A Randomized Controlled Trial. <i>Spine</i> , 2006, 31, 377-381.	2.0	73
18	EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. <i>RMD Open</i> , 2019, 5, e001014.	3.8	73

#	ARTICLE	IF	CITATIONS
19	Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 105.	3.5	73
20	The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: A population-based study. <i>Arthritis and Rheumatism</i> , 2006, 54, 54-59.	6.7	72
21	Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. <i>Rheumatology</i> , 2015, 54, 1664-1672.	1.9	72
22	Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab. <i>JAMA Neurology</i> , 2022, 79, 399.	9.0	67
23	Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, 1579-1585.	1.9	63
24	Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype. <i>PLoS ONE</i> , 2017, 12, e0175109.	2.5	61
25	The role of female hormonal factors in the development of rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, kew318.	1.9	55
26	EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 69-76.	0.9	55
27	Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 518-526.	0.9	54
28	Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 238-241.	0.9	54
29	Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the JAK-pot™ collaboration. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1358-1366.	0.9	48
30	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 476-479.	0.9	47
31	Impaired response to treatment with tumour necrosis factor inhibitors in smokers with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 532-539.	0.9	45
32	Periodontal status correlates with anti-citrullinated protein antibodies in first-degree relatives of individuals with rheumatoid arthritis. <i>Journal of Clinical Periodontology</i> , 2019, 46, 690-698.	4.9	43
33	The impact of obesity on the development and progression of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1911-1913.	0.9	42
34	The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. <i>Rheumatology</i> , 2021, 60, 820-828.	1.9	41
35	Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient Preferences. <i>Current Rheumatology Reports</i> , 2016, 18, 51.	4.7	39
36	Environmental factors and hormones in the development of rheumatoid arthritis. <i>Seminars in Immunopathology</i> , 2017, 39, 461-468.	6.1	39

#	ARTICLE	IF	CITATIONS
37	Performance of an automated computer-based scoring method to assess joint space narrowing in rheumatoid arthritis: A longitudinal study. <i>Arthritis and Rheumatism</i> , 2006, 54, 1444-1450.	6.7	34
38	Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. <i>Joint Bone Spine</i> , 2010, 77, 313-318.	1.6	34
39	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1160-1166.	0.9	34
40	Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the European-European registry collaboration for abatacept (PANABA). <i>Clinical Rheumatology</i> , 2017, 36, 773-779.	2.2	33
41	At the horizon of innovative therapy in rheumatology: new biologic agents. <i>Current Opinion in Rheumatology</i> , 2008, 20, 269-275.	4.3	32
42	Joint Damage Progression in Patients with Rheumatoid Arthritis in Clinical Remission. Do Biologics Perform Better Than Synthetic Antirheumatic Drugs?. <i>Journal of Rheumatology</i> , 2014, 41, 1576-1582.	2.0	31
43	Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort. <i>Journal of Rheumatology</i> , 2018, 45, 506-512.	2.0	31
44	EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1286-1298.	0.9	31
45	Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendations. <i>RMD Open</i> , 2019, 5, e001004.	3.8	30
46	Preferences of Patients and At-risk Individuals for Preventive Approaches to Rheumatoid Arthritis. <i>Clinical Therapeutics</i> , 2019, 41, 1346-1354.	2.5	28
47	Primary prevention of rheumatoid arthritis: A qualitative study in a high-risk population. <i>Joint Bone Spine</i> , 2013, 80, 673-674.	1.6	25
48	The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2141-2150.	5.6	25
49	Preventing rheumatoid arthritis: Preferences for and predicted uptake of preventive treatments among high risk individuals. <i>PLoS ONE</i> , 2019, 14, e0216075.	2.5	25
50	Early inflammatory arthritis versus rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2009, 21, 118-123.	4.3	22
51	Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: Table 1. <i>Rheumatology</i> , 2016, 56, kew271.	1.9	22
52	Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?. <i>RMD Open</i> , 2019, 5, e000994.	3.8	22
53	Immune-mediated experimental arthritis in IL-33 deficient mice. <i>Cytokine</i> , 2014, 69, 68-74.	3.2	20
54	The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017, 36, 677-682.	2.2	20

#	ARTICLE	IF	CITATIONS
55	Prevention of Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, 771-785.	1.9	19
56	Primary and secondary non-response: in need of operational definitions in observational studies. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 961-964.	0.9	18
57	Personalized prediction of disease activity in patients with rheumatoid arthritis using an adaptive deep neural network. <i>PLoS ONE</i> , 2021, 16, e0252289.	2.5	18
58	Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III Trial. <i>Arthritis Care and Research</i> , 2018, 70, 861-868.	3.4	17
59	Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider. <i>RMD Open</i> , 2018, 4, e000756.	3.8	17
60	Initial validation and results of the Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: a EULAR project. <i>RMD Open</i> , 2018, 4, e000641.	3.8	17
61	Glucocorticoid injections for greater trochanteric pain syndrome: a randomised double-blind placebo-controlled (GLUTEAL) trial. <i>Clinical Rheumatology</i> , 2019, 38, 647-655.	2.2	17
62	Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1680.2-1685.	0.9	16
63	EULAR "points to consider"™ for the conduction of workforce requirement studies in rheumatology. <i>RMD Open</i> , 2018, 4, e000780.	3.8	16
64	Preferences for treatments to prevent rheumatoid arthritis in Canada and the influence of shared decision-making. <i>Clinical Rheumatology</i> , 2020, 39, 2931-2941.	2.2	15
65	Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritis. <i>BMJ Open</i> , 2021, 11, e048409.	1.9	15
66	Anti-Cyclic Citrullinated Peptide Antibodies in the Diagnosis of Rheumatoid Arthritis: Bayes Clears the Haze. <i>Annals of Internal Medicine</i> , 2007, 146, 816.	3.9	15
67	Ultrasound is not associated with the presence of systemic autoimmunity or symptoms in individuals at risk for rheumatoid arthritis. <i>RMD Open</i> , 2019, 5, e000922.	3.8	14
68	Impact of assessing patient-reported outcomes with mobile apps on patient-provider interaction. <i>RMD Open</i> , 2021, 7, e001566.	3.8	14
69	Is the prevention of rheumatoid arthritis possible?. <i>Clinical Rheumatology</i> , 2020, 39, 1383-1389.	2.2	14
70	The Role of Nutritional Factors and Intestinal Microbiota in Rheumatoid Arthritis Development. <i>Nutrients</i> , 2021, 13, 96.	4.1	14
71	Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM). <i>Clinical Rheumatology</i> , 2017, 36, 59-66.	2.2	13
72	Measuring ACPA in the general population or primary care: is it useful?. <i>RMD Open</i> , 2020, 6, e001085.	3.8	13

#	ARTICLE	IF	CITATIONS
73	Associations between serum antibodies to periodontal pathogens and preclinical phases of rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 4755-4764.	1.9	13
74	Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy. <i>Rheumatology</i> , 2022, 62, 89-97.	1.9	13
75	EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 780-785.	0.9	12
76	Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution. <i>Rheumatology</i> , 2019, 58, 2221-2229.	1.9	11
77	Response to: "Non-causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study" by Inamo. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e104-e104.	0.9	10
78	Mini-Review: Human Microbiome and Rheumatic Diseases. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 491160.	3.9	10
79	Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: Results from the Swiss SCQM registry. <i>Joint Bone Spine</i> , 2013, 80, 160-164.	1.6	9
80	Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis. <i>Medical Decision Making</i> , 2018, 38, 719-729.	2.4	8
81	Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: results from the SCQM cohort. <i>Rheumatology</i> , 2019, 58, 432-440.	1.9	8
82	Comparison of Psoriatic Arthritis and Rheumatoid Arthritis Patients across Body Mass Index Categories in Switzerland. <i>Journal of Clinical Medicine</i> , 2021, 10, 3194.	2.4	8
83	Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1472-1479.	0.9	7
84	Cognitive-bias modification intervention to improve physical activity in patients following a rehabilitation programme: protocol for the randomised controlled IMPACT trial. <i>BMJ Open</i> , 2021, 11, e053845.	1.9	7
85	An Internet-based technique for the identification of persons with symptoms of inflammatory polyarthritis of less than 12 weeks. <i>Clinical Rheumatology</i> , 2015, 34, 465-470.	2.2	6
86	Chagas disease and systemic autoimmune diseases among Bolivian patients in Switzerland. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2018, 113, e170383.	1.6	6
87	The links of hepcidin and erythropoietin in the interplay of inflammation and iron deficiency in a large observational study of rheumatoid arthritis. <i>British Journal of Haematology</i> , 2019, 186, 101-112.	2.5	6
88	Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab. <i>RMD Open</i> , 2021, 7, e001711.	3.8	6
89	Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 729-736.	0.9	6
90	Predictive factors of treatment persistence in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2020, 87, 531-534.	1.6	5

#	ARTICLE	IF	CITATIONS
91	Response to "Correspondence on "Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort"™ by Ruysen-Witrand et al. Annals of the Rheumatic Diseases, 2023, 82, e33-e33.	0.9	4
92	Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients. Rheumatology Advances in Practice, 2021, 5, rkab087.	0.7	4
93	Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. RMD Open, 2021, 7, e001818.	3.8	4
94	Comparative Effectiveness of Rheumatoid Arthritis Therapies. Current Rheumatology Reports, 2010, 12, 348-354.	4.7	3
95	Small studies overestimate the benefit of therapies for OA. Nature Reviews Rheumatology, 2010, 6, 617-618.	8.0	3
96	Comparative effectiveness of biologic antirheumatic therapies in rheumatoid arthritis after failure to respond to a first TNF inhibitor. Journal of Comparative Effectiveness Research, 2012, 1, 481-484.	1.4	2
97	OP0105...HPR DO MOBILE APPS IMPROVE SHARED DECISION MAKING AND DISEASE MANAGEMENT IN THE RHEUMATIC DISEASES? AN EVALUATION OF APPS IN A SWISS RHEUMATOLOGY REGISTRY. , 2019, , .		2
98	Menopause and Possible Effect on Association Between Age and Anticyclic Citrullinated Peptide Antibodies in Women At Risk of Rheumatoid Arthritis. Journal of Rheumatology, 2020, 47, 300.1-300.	2.0	2
99	Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a descriptive cohort study assessing trends in patient characteristics in Switzerland. BMJ Open, 2022, 12, e056352.	1.9	2
100	Periodontitis in First Degree-Relatives of Individuals With Rheumatoid Arthritis: A Short Narrative Review. Frontiers in Oral Health, 2022, 3, .	3.0	2
101	87. "Comparative Efficacy of Novel Disease-Modifying Antirheumatic Drugs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with an Inadequate Response to Traditional Dmards: A Network Meta-Analysis. Rheumatology, 2014, 53, i88-i89.	1.9	1
102	SAT0102...ASSOCIATION BETWEEN BASELINE HAEMOGLOBIN LEVELS AND RADIOGRAPHIC JOINT DAMAGE PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BARICITINIB OR STANDARD OF CARE. , 2019, , .		1
103	Identification of biological pathways specific to phases preceding rheumatoid arthritis development through gene expression profiling. International Journal of Immunogenetics, 2021, 48, 239-249.	1.8	1
104	Mazzotti reaction: Ivermectin-associated polyarthritis after delayed scabies treatment. Case report and review of the literature. Therapie, 2021, , .	1.0	1
105	New viral outbreaks: time for rheumatologists to get involved?. Rheumatology, 2017, 56, 2046-2047.	1.9	1
106	Inflammation and autoimmune responses are independent of peripheral MHC class II expression driven by CIITA pIV in collagen induced arthritis. Annals of the Rheumatic Diseases, 2011, 70, A25-A25.	0.9	0
107	FRIO162...BASELINE CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH ANAEMIA IN CLINICAL STUDIES OF TOFACITINIB IN RHEUMATOID ARTHRITIS. , 2019, , .		0
108	AB0274...THE PREDICTIVE VALUE OF RHEUMATOID FACTOR, ANTI-CITRULLINATED PROTEIN ANTIBODIES, ANTI-CARBAMYLATED PROTEIN: ANTIBODIES AND ANTI-PEPTIDYL ARGININE DEIMINASE TYPE-3 ANTIBODIES, ALONE OR IN COMBINATION, ON RADIOGRAPHIC DAMAGE IN RHEUMATOID ARTHRITIS. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
109	FRI0655â€¦THE IMPACT OF PREGNANCY ON STRUCTURAL PROGRESSION IN PREMENOPAUSAL WOMEN WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
110	Response to: â€œCorrespondence on â€œ <i>Prevotella copri</i> in individuals at risk for rheumatoid arthritisâ€™â€™ by Sun and Ni. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e51-e51.	0.9	0
111	P188â€¦Baricitinib effectiveness after a previous inadequate response to an alternative JAK inhibitor: results from the Swiss rheumatoid arthritis register. <i>Rheumatology</i> , 2022, 61, .	1.9	0